Human IgG and IgA responses to COVID-19 mRNA vaccines
Open Access
- 16 June 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (6), e0249499
- https://doi.org/10.1371/journal.pone.0249499
Abstract
SARS-CoV-2 spike antigen-specific IgG and IgA elicited by infection mediate viral neutralization and are likely an important component of natural immunity, however, limited information exists on vaccine induced responses. We measured COVID-19 mRNA vaccine induced IgG and IgA in serum serially, up to 145 days post vaccination in 4 subjects. Spike antigen-specific IgG levels rose exponentially and plateaued 21 days after the initial vaccine dose. After the second vaccine dose IgG levels increased further, reaching a maximum approximately 7–10 days later, and remained elevated (average of 58% peak levels) during the additional >100 day follow up period. COVID-19 mRNA vaccination elicited spike antigen-specific IgA with similar kinetics of induction and time to peak levels, but more rapid decline in serum levels following both the 1st and 2nd vaccine doses (nd shot). The data demonstrate COVID-19 mRNA vaccines effectively induce spike antigen specific IgG and IgA and highlight marked differences in their persistence in serum.Funding Information
- National Institute for Occupational Safety and Health (5T03OH008607-15)
This publication has 27 references indexed in Scilit:
- IgG Subclasses and Allotypes: From Structure to Effector FunctionsFrontiers in Immunology, 2014
- IgA subclass switch recombination in human mucosal and systemic immune compartmentsMucosal Immunology, 2014
- Comparison of Antiviral Activity between IgA and IgG Specific to Influenza Virus Hemagglutinin: Increased Potential of IgA for Heterosubtypic ImmunityPLOS ONE, 2014
- CCR10 and its ligands in regulation of epithelial immunity and diseasesProtein & Cell, 2012
- Antibodies and B Cell Memory in Viral ImmunityImmunity, 2007
- IgAPublished by Elsevier BV ,1998
- The half-lives of IgG subclasses and specific antibodies in patients with primary immunodeficiency who are receiving intravenously administered immunoglobulin.1988
- Immunoglobulins in the lung.Thorax, 1986
- Cross‐protection in mice infected with influenza A virus by the respiratory route is correlated with local IgA antibody rather than serum antibody or cytotoxic T cell reactivityEuropean Journal of Immunology, 1984
- A study of plasma proteins in the sol phase of sputum from patients with chronic bronchitis.Thorax, 1979